Savara Inc Quick Ratio (SVRA) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Savara Inc   (NASDAQ: SVRA)

Savara Inc 's Quick Ratio

SVRA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 9.83 below Savara Inc average.

Within Major Pharmaceutical Preparations industry 107 other companies have achieved higher Quick Ratio than Savara Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 307 to 470.

Explain Quick Ratio?
How much Cash & cash equivalents SVRA´s has?
What are SVRA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SVRA Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 29.14 % 30.6 % 38.52 % 31.04 % 20.75 %
Y / Y Cash & cash equivalent Change 18.16 % 17.55 % 20.06 % -43.32 % 20.51 %
Quick Ratio MRQ 9.83 13.05 11.56 7.42 10.75
SVRA's Total Ranking # 470 # 307 # 201 # 407 # 237
Seq. Current Liabilities Change 13.26 % -23.81 % 21.72 % 22.96 % 14.54 %
Seq. Cash & cash equivalent Change -14.67 % -13.97 % 89.49 % -15.06 % -15.11 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 108
Healthcare Sector # 166
Overall Market # 470


Quick Ratio Statistics
High Average Low
38.43 13.33 0.55
(Jun 30 2022)   (Jun 30 2016)




Financial Statements
Savara Inc 's Current Liabilities $ 18 Millions Visit SVRA's Balance sheet
Savara Inc 's Cash & cash equivalent $ 173 Millions Visit SVRA's Balance sheet
Source of SVRA's Sales Visit SVRA's Sales by Geography


Cumulative Savara Inc 's Quick Ratio

SVRA's Quick Ratio for the trailling 12 Months

SVRA Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 32.53 % 30.82 % 28.95 % 28.16 % 30.46 %
Y / Y Cash & cash equivalent TTM Growth 0.16 % -0.07 % -0.19 % -1.03 % 23.45 %
Quick Ratio TTM 10.47 10.7 10.83 11.22 13.85
Total Ranking TTM # 3835 # 2360 # 2547 # 2415 # 2307
Seq. Current Liabilities TTM Growth 5.99 % 5.81 % 9.95 % 7.48 % 4.62 %
Seq. Cash & cash equivalent TTM Growth 3.75 % 4.46 % 6.16 % -12.94 % 3.51 %

Quick ratio ranking by company, industry and sector >> Back to SVRA Financial Strength Comparisons >> Go to Compare SVRA Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q2 2026 to $17.60 millions, cumulative Quick Ratio decreased to 10.47 above the SVRA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Savara Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2360 to 3835.

Explain Quick Ratio?
How much Cash & cash equivalents SVRA´s has?
What are SVRA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 433
Healthcare Sector # 884
Within the Market # 3835


trailing twelve months Quick Ratio Statistics
High Average Low
15.32 4.73 0.76
(Mar 31 2023)   (Sep 30 2016)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Shattuck Labs Inc   26.94 $ 208.300  Millions$ 7.731  Millions
Cryoport inc   26.87 $ 785.860  Millions$ 29.244  Millions
Roivant Sciences Ltd   26.82 $ 7,607.076  Millions$ 283.603  Millions
Palvella Therapeutics Inc   26.23 $ 313.381  Millions$ 11.947  Millions
Upstream Bio Inc   26.16 $ 261.307  Millions$ 9.988  Millions
Rallybio Corporation  26.02 $ 92.800  Millions$ 3.567  Millions
Assembly Biosciences Inc   25.95 $ 608.475  Millions$ 23.445  Millions
Arbutus Biopharma Corp  25.84 $ 92.625  Millions$ 3.585  Millions
Immix Biopharma Inc   25.49 $ 238.715  Millions$ 9.364  Millions
Boundless Bio Inc   25.00 $ 194.230  Millions$ 7.768  Millions
Sionna Therapeutics Inc   24.88 $ 268.300  Millions$ 10.782  Millions
Prothena Corporation Public Limited Company  24.72 $ 288.193  Millions$ 11.658  Millions
Zenas Biopharma Inc   24.28 $ 1,597.761  Millions$ 65.818  Millions
Neuphoria Therapeutics Inc   23.89 $ 19.866  Millions$ 0.832  Millions
Innoviva Inc   23.77 $ 1,118.871  Millions$ 47.064  Millions
Pepgen Inc   23.51 $ 211.674  Millions$ 9.005  Millions
Kailera Therapeutics Inc   23.41 $ 1,958.240  Millions$ 83.651  Millions
Equillium Inc   23.07 $ 57.164  Millions$ 2.478  Millions
Relmada Therapeutics Inc  21.72 $ 217.731  Millions$ 10.023  Millions
Keros Therapeutics Inc   21.20 $ 257.606  Millions$ 12.153  Millions
Protagonist Therapeutics inc   21.05 $ 782.576  Millions$ 37.181  Millions
Stablecoin Development Corporation  20.76 $ 7.122  Millions$ 0.343  Millions
Rhythm Pharmaceuticals Inc   20.65 $ 596.183  Millions$ 28.868  Millions
Structure Therapeutics Inc   20.31 $ 1,342.700  Millions$ 66.113  Millions
Scynexis Inc   19.69 $ 114.696  Millions$ 5.825  Millions
Q32 Bio Inc   19.68 $ 106.270  Millions$ 5.401  Millions
Damora Therapeutics Inc   19.62 $ 540.515  Millions$ 27.550  Millions
Kairos Pharma Ltd   19.12 $ 5.067  Millions$ 0.265  Millions
Minerva Neurosciences Inc   19.02 $ 75.267  Millions$ 3.958  Millions
Abcellera Biologics Inc   18.05 $ 960.143  Millions$ 53.189  Millions

Date modified: 2026-09-08T22:28:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.